Amarin (AMRN) Stock Rating Upgraded by BidaskClub

Among 4 analysts covering Amarin Corp (NASDAQ:AMRN), 4 have Buy rating, 0 Sell and 0 Hold. Three analysts have provided estimates for Amarin's earnings.

Whereas they predicted High and Low Earnings Estimate as $-0.03 and $-0.05 respectively.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, November 1st.

Delhi dentist bites, beats, burns minor maid; is arrested
Further, she had vicious bite marks all over her face which she informed had been made by her lady employer in anger. In another tweet, she said: "A doctor herself, how could she torture a 14-year-old in such a brutal manner.

On average, analysts expect that Amarin will report full-year earnings of ($0.22) per share for the current year, with EPS estimates ranging from ($0.22) to ($0.20). The company's revenue was up 45.4% compared to the same quarter last year. equities research analysts predict that Amarin Co. plc will post -0.22 earnings per share for the current fiscal year. Zacks' earnings per share averages are an average based on a survey of research analysts that that provide coverage for Amarin.

Amarin (AMRN) opened at $4.25 on Friday. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road. The business had revenue of $47.10 million during the quarter, compared to analysts' expectations of $45.85 million. The business's revenue for the quarter was up 45.4% compared to the same quarter previous year. During the same quarter in the previous year, the business earned ($0.08) EPS.

A number of brokerages have commented on AMRN. BidaskClub raised Amarin from a "sell" rating to a "hold" rating in a report on Thursday. ValuEngine upgraded shares of Amarin from a "sell" rating to a "hold" rating in a research note on Wednesday, December 20th. Seaport Global Securities upgraded the shares of RES in report on Tuesday, October 4 to "Neutral" rating. Cantor Fitzgerald reaffirmed a buy rating and set a $10.00 price target on shares of Amarin in a research report on Tuesday, September 26th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Amarin in a report on Thursday, November 2nd. Out of rating recommendations 2 have given the stock a Buy while 3 recommend the stock as Outperform. Amarin presently has a consensus rating of Buy and an average target price of $7.75. Jefferies initiated Amarin Corporation plc (NASDAQ:AMRN) rating on Thursday, May 12. About 1.01 million shares traded. The last close places the company's stock about $0.17 off its 52 week high of $4.47 and $1.49 above the 52 week low of $2.81. The company has a quick ratio of 1.32, a current ratio of 1.63 and a debt-to-equity ratio of -1.48.

Derry Girls gets a second series
McGee previously wrote for Being Human , and then went on to create another great show for Channel 4 , London Irish . A lot of people said episode two of Derry Girls was even better than the first. .

In other news, insider Steven B. Ketchum sold 63,479 shares of the company's stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $4.40, for a total transaction of $284,605.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider John F. Thero purchased 10,000 shares of the firm's stock in a transaction on Thursday, November 30th. The shares were purchased at an average cost of $3.24 per share, with a total value of $32,400.00. It is positive, as 10 investors sold AMRN shares while 21 reduced holdings. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company's stock valued at $114,000 after purchasing an additional 300 shares in the last quarter. State Street Corp grew its position in shares of Amarin by 1.3% in the second quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company's stock valued at $152,000 after purchasing an additional 5,000 shares in the last quarter. Dynamic Technology Lab Private Ltd grew its position in shares of Amarin by 94.2% in the second quarter. The company's Relative Strength Index which shows price strength now stands at 67.62. Cubist Systematic Strategies LLC bought a new stake in Amarin during the third quarter worth approximately $226,000. Institutional investors and hedge funds own 40.12% of the company's stock. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & worldwide copyright & trademark law.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The companyÂ's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Swansea boss Carvalhal mixed emotions after Newcastle draw
"Sometimes the fans can stay a little nervous if the team is not in a good way". We are playing better, with more confidence and a better dynamic".

Últimas notícias